16,882 results match your criteria booster vaccination


Mandatory Infant Vaccinations in France During the COVID-19 Pandemic in 2020.

Front Pediatr 2021 28;9:666848. Epub 2021 May 28.

EPI-PHARE (French National Agency for Medicines and Health Products Safety, ANSM; and French National Health Insurance, CNAM), Saint-Denis, France.

To describe changes in the dispensation of 11 mandatory vaccines to infants in France during the COVID-19 pandemic in 2020, considering the priming doses and boosters separately. With data from the French national health database, all dispensations of priming doses and boosters of 11 mandatory vaccines [penta/hexavalent, measles mumps rubella (MMR), meningococcal conjugate type-C (Men-C-C), 13-valent pneumococcal conjugate (PCV13)] for infants ≤24 months old were aggregated by 4-week periods in 2020. Expected counts in 2020 were estimated according to counts in 2019 weighted by a ratio considering the level of vaccine dispensation before the pandemic onset in 2020. Read More

View Article and Full-Text PDF

Geographical variations and associated factors of defaulting from immunization among children aged 12 to 23 months in Ethiopia: using spatial and multilevel analysis of 2016 Ethiopian Demographic and Health Survey.

Environ Health Prev Med 2021 Jun 12;26(1):65. Epub 2021 Jun 12.

Department of Nursing, College of Health Sciences, Salale University, Fitche, Ethiopia.

Background: In Ethiopia, despite the considerable improvement in immunization coverage, the burden of defaulting from immunization among children is still high with marked variation among regions. However, the geographical variation and contextual factors of defaulting from immunization were poorly understood. Hence, this study aimed to identify the spatial pattern and associated factors of defaulting from immunization. Read More

View Article and Full-Text PDF

Human papillomavirus in Italy: retrospective cohort analysis and preliminary vaccination effect from real-world data.

Eur J Health Econ 2021 Jun 12. Epub 2021 Jun 12.

Institute for Leadership and Management in Health, Kingston University London, London, UK.

Introduction: The objective of this study was to estimate the lifetime risk of hospitalization associated with all major human papillomavirus (HPV)-related diseases in Italy. Moreover, a preliminary vaccination effect was also performed.

Methods: A retrospective, nonrandomized, observational study was developed based on patients hospitalized between 2006 and 2018 in Italy. Read More

View Article and Full-Text PDF

Antibody response to inactivated COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled study among hospital workers and elderly.

Rheumatol Int 2021 Jun 9. Epub 2021 Jun 9.

Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, 81310, Turkey.

Objective: To assess antibody response to inactivated COVID-19 vaccine in patients with immune-mediated diseases (IMD) among hospital workers and people aged 65 and older.

Methods: In this cross-sectional study, we studied 82 hospital workers with IMD (mean age: 42.2 ± 10. Read More

View Article and Full-Text PDF

Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine.

EClinicalMedicine 2021 Jun 4:100928. Epub 2021 Jun 4.

Scientific Direction, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), Rome, Italy.

Background: Literature data suggests that age, gender and body mass index (BMI) could be associated with difference in immune responses to vaccines. The first goal of the study was to analyze the antibody titre seven days after the second dose of BNT162b2 vaccine in a group of 248 healthcare workers (HCWs). The second goal was to analyze how antibody titre changes in correlation with age, gender, BMI and hypertension. Read More

View Article and Full-Text PDF

Heterologous immunization with Covishield and Pfizer vaccines against SARS-CoV-2 elicits a robust humoral immune response.

J Infect Dev Ctries 2021 05 31;15(5):653-656. Epub 2021 May 31.

Department of Microbiology and Immunology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.

Understanding the efficacy and durability of heterologous immunization schedules against SARS-CoV-2 is critical, as supply demands and vaccine choices become significant issues in the global vaccination strategy. Here we characterize the neutralizing antibodies produced in two subjects who received combination immunizations against SARS-CoV-2, first with Covishield (Oxford-AstraZeneca) vaccine, followed 33 days later with a second dose (booster) shot of the Pfizer-BioNTech vaccine. Serum samples were collected 25 days following the primary vaccination and 13 days after the secondary Pfizer vaccination. Read More

View Article and Full-Text PDF

Knowledge, attitudes and practices of smallholder farmers on foot and mouth disease control in two Cambodian provinces.

Transbound Emerg Dis 2021 Jun 8. Epub 2021 Jun 8.

Independent Livestock Consultant, Pursat, Cambodia.

Food-and-mouth disease (FMD) is endemic in Cambodia. The control programme for FMD has relied on vaccination, with poor vaccination uptake by smallholder farmers becoming an increasing concern. A study to improve the understanding of farmer knowledge, attitudes and practices of FMD control and vaccination was conducted in two Cambodian provinces (Kampong Cham and Pursat). Read More

View Article and Full-Text PDF

Impaired humoral and cellular immunity after SARS-CoV2 BNT162b2 (Tozinameran) prime-boost vaccination in kidney transplant recipients.

J Clin Invest 2021 Jun 8. Epub 2021 Jun 8.

Department for General and Visceral Surgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Novel mRNA-based vaccines have been proven powerful tools to combat the global pandemic caused by SARS-CoV2 with BNT162b2 (trade name: Comirnaty) efficiently protecting individuals from COVID-19 across a broad age range. Still, it remains largely unknown how renal insufficiency and immunosuppressive medication affect development of vaccine induced immunity. We therefore comprehensively analyzed humoral and cellular responses in kidney transplant recipients after the standard second vaccination dose. Read More

View Article and Full-Text PDF

Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study.

J Parkinsons Dis 2021 May 27. Epub 2021 May 27.

AFFiRiS AG, Vienna, Austria.

Background: Immunotherapies targeting α-synuclein aim to limit its extracellular spread in the brain and prevent progression of pathology in Parkinson's disease (PD). PD03A is a specific active immunotherapy (SAIT) involving immunization with a short peptide formulation.

Objective: This phase 1 study characterized the safety and tolerability of PD03A in patients with early PD. Read More

View Article and Full-Text PDF

Health inequities related to vaccination: An evidence map of potentially influential factors and systematic review of interventions.

Vaccine 2021 Jun 3. Epub 2021 Jun 3.

Alberta Research Centre for Health Evidence (ARCHE), Department of Pediatrics, University of Alberta, Edmonton, Canada.

Introduction: The National Advisory Committee on Immunization (NACI) makes recommendations for vaccines in Canada. To inform considerations for equity when making recommendations, the NACI Secretariat developed a matrix of factors that may influence vaccine equity. To inform the matrix we mapped the evidence for PROGRESS And Other factors potentially associated with unequal levels of illness or death from vaccine-preventable diseases (VPDs) and systematically reviewed the evidence for interventions aimed at reducing inequities. Read More

View Article and Full-Text PDF

Individual and community-level determinants of poor tetanus toxoid immunization among pregnant women in Ethiopia using data from 2016 Ethiopian demographic and health survey; multilevel analysis.

Arch Public Health 2021 Jun 4;79(1):92. Epub 2021 Jun 4.

Department of midwifery, school of nursing and midwifery, college of medicine and health sciences, Wollo University, Dessie, Ethiopia.

Background: Tetanus is a vaccine-preventable disease that can occur in all populations, with neonates and pregnant women being at the most risk. Ethiopia has the highest maternal and neonatal tetanus morbidity and mortality rates. Besides, only 49% of mothers get vaccinated with adequate tetanus toxoid in Ethiopia which is below the world health organization recommendation. Read More

View Article and Full-Text PDF

Rekonvaleszenten-Plasma mildert COVID-19-Verlauf bei Älteren.

Authors:
Georg Nilius

MMW Fortschr Med 2021 06;163(11):28

Evangelische Kliniken Essen-Mitte, Am Deimelsberg 34 a, 45726, Essen, Deutschland.

View Article and Full-Text PDF

Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study.

Hum Vaccin Immunother 2021 Jun 4:1-10. Epub 2021 Jun 4.

Global Clinical Development, Sanofi Pasteur, Swiftwater, PA, USA.

Booster doses of meningococcal conjugate vaccines induce long-term protection against invasive meningococcal disease. We evaluated the immunogenicity and safety of a booster dose of MenACYW-TT in pre-school children who were primed 3 years earlier with MenACYW-TT or MCV4-TT (Nimenrix®). In this Phase III, open-label, multi-center study (NCT03476135), children (4-5 years old), who received a primary dose of MenACYW-TT or MCV4-TT as toddlers in a previous study, received a booster dose of MenACYW-TT. Read More

View Article and Full-Text PDF

lncRNA028466 regulates Th1/Th2 cytokine expression and associates with Echinococcus granulosus antigen P29 immunity.

Parasit Vectors 2021 Jun 3;14(1):295. Epub 2021 Jun 3.

Center of Scientific Technology of Ningxia Medical University, Yinchuan, 750004, Ningxia Hui Autonomous Region, People's Republic of China.

Background: Cystic echinococcosis (CE) is a parasitic disease that is caused by Echinococcus granulosus (Eg). The recombinant Echinococcus granulosus antigen P29 (rEg.P29) was shown to confer effective immunity to sheep and mice during E. Read More

View Article and Full-Text PDF

IMMUNO-COV v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody Titers.

mSphere 2021 Jun 2:e0017021. Epub 2021 Jun 2.

Imanis Life Sciences, Rochester, Minnesota, USA.

Neutralizing antibodies are key determinants of protection from future infection, yet well-validated high-throughput assays for measuring titers of SARS-CoV-2-neutralizing antibodies are not generally available. Here, we describe the development and validation of IMMUNO-COV v2.0, a scalable surrogate virus assay, which titrates antibodies that block infection of Vero-ACE2 cells by a luciferase-encoding vesicular stomatitis virus displaying SARS-CoV-2 spike glycoproteins (VSV-SARS2-Fluc). Read More

View Article and Full-Text PDF

Epidemiology of Diphtheria in Yemen, 2017-2018: Surveillance Data Analysis.

JMIR Public Health Surveill 2021 Jun 2;7(6):e27590. Epub 2021 Jun 2.

Department of Community Medicine, Public Health and Family Medicine, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.

Background: As a consequence of war and the collapse of the health system in Yemen, which prevented many people from accessing health facilities to obtain primary health care, vaccination coverage was affected, leading to a deadly diphtheria epidemic at the end of 2017.

Objective: This study aimed to describe the epidemiology of diphtheria in Yemen and determine its incidence and case fatality rate.

Methods: Data were obtained from the diphtheria surveillance program 2017-2018, using case definitions of the World Health Organization. Read More

View Article and Full-Text PDF

The Uro-oncology Patient and Vaccination Against SARS-CoV-2.

Eur Urol Open Sci 2021 Jul 27;29:77-81. Epub 2021 May 27.

Department of Urology, Hospital Clínico San Carlos, Madrid, Spain.

As of April 13, 2021, 137 million cases of COVID-19 and 2.95 million deaths have been reported worldwide. On December 21, 2020, the Pfizer-BioNTech vaccine was approved for use in the European Union, with efficacy of 95% protection against COVID-19 infection. Read More

View Article and Full-Text PDF

M448R and MGF505-7R: Two African Swine Fever Virus Antigens Commonly Recognized by ASFV-Specific T-Cells and with Protective Potential.

Vaccines (Basel) 2021 May 14;9(5). Epub 2021 May 14.

IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.

African swine fever (ASF) is today's number one threat for the global swine industry. Neither commercial vaccine nor treatment is available against ASF and, thus far, only live attenuated viruses (LAV) have provided robust protection against lethal ASF virus (ASFV) challenge infections. Identification of ASFV proteins inducing protective immune responses is one of the major challenges to develop safer and efficient subunit vaccines. Read More

View Article and Full-Text PDF

Risk of Absence of Measles Antibody in Healthcare Personnel and Efficacy of Booster Vaccination.

Vaccines (Basel) 2021 May 12;9(5). Epub 2021 May 12.

Ewha Education and Research Center for Infection, Seoul 07985, Korea.

We aimed to identify the presence of the measles IgG antibody (mIgG-Ab) in healthcare personnel and finding out who needs the measles vaccination. The history of measles vaccination was obtained from the national vaccine registry. A baseline mIgG-Ab test was performed, and the measles vaccine was administered to participants who tested negative or equivocal for mIgG-Abs. Read More

View Article and Full-Text PDF

Pharmacokinetics of α-Pyrrolidinovalerophenone in Male Rats with and without Vaccination with an α-Pyrrolidinovalerophenone Vaccine.

J Pharm Pharm Sci 2021 ;24:267-276

University of Arkansas for Medical Sciences.

Purpose: α-Pyrrolidinovalerophenone (α-PVP) is a second-generation synthetic cathinone which acts as an inhibitor at the dopamine and norepinephrine transporters in the brain. These novel studies determined the pharmacokinetics (PK) of α-PVP in rats and then evaluated the effects of an α-PVP vaccine on the PK profile.

Methods: Adult male Sprague-Dawley rats were randomly divided into treatment groups (n = 24/group) in which the vaccinated rats received an initial and two booster immunizations of the α-PVP vaccine at 0, 3, and 9 wks. Read More

View Article and Full-Text PDF
January 2021

Intensified antibody response elicited by boost suggests immune memory in individuals administered two doses of SARS-CoV-2 inactivated vaccine.

Emerg Microbes Infect 2021 Dec;10(1):1112-1115

Institute of Medical Biology, Chinese Academy of Medicine Sciences and Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development for Severe Infectious Diseases, Kunming, People's Republic of China.

Neutralizing antibodies in the subjects of an inactivated SARS-CoV-2 vaccine clinical trial showed a decreasing trend over months. An investigation studying the third immunization suggested that the waning of neutralizing antibodies in individuals administered two doses of inactivated vaccine does not mean the disappearance of immunity. Read More

View Article and Full-Text PDF
December 2021

Evaluation of a measles vaccination campaign at the universities in the city of Zurich, 2019.

Public Health 2021 May 27;195:51-53. Epub 2021 May 27.

Epidemiology, Biostatistics and Prevention Institute, Department of Public and Global Health, University of Zurich, Zurich, Switzerland; Department of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, Switzerland.

Objectives: In 2019, there were 29 reported cases of measles in the Canton of Zurich, with two cases occurring among university students. In collaboration with the University of Zurich Travel Clinic, the Health Department of the Canton of Zurich offered free measles vaccination to all employees and students at the University of Zurich (UZH) and the Swiss Federal Institute of Technology (ETH). This short communication shares the results of this large measles vaccination campaign. Read More

View Article and Full-Text PDF

A systems map of the economic considerations for vaccination: Application to hard-to-reach populations.

Vaccine 2021 May 24. Epub 2021 May 24.

Public Health Informatics, Computational, and Operations Research (PHICOR), City University of New York (CUNY) Graduate School of Public Health and Health Policy, New York City, NY, United States. Electronic address:

Background: Understanding the economics of vaccination is essential to developing immunization strategies that can be employed successfully with limited resources, especially when vaccinating populations that are hard-to-reach.

Methods: Based on the input from interviews with 24 global experts on immunization economics, we developed a systems map of the mechanisms (i.e. Read More

View Article and Full-Text PDF

Vaccine wastage at primary, secondary, and tertiary level of healthcare system-A study from Northern India.

J Family Med Prim Care 2021 Feb 27;10(2):877-882. Epub 2021 Feb 27.

Department of Community Medicine, Dayanand Medical College and Hospital, Ludhiana, Punjab, India.

Background: High vaccine wastage results in escalation of budget of immunization program.

Objective: To analyze vaccine wastage at three levels of service delivery under public sector, such as at district level, community health Centre (CHC), and sub center (SC).

Study Design: A retrospective cross-sectional record based study in a north Indian state. Read More

View Article and Full-Text PDF
February 2021

The economic burden of pneumonia in children under five in Uganda.

Vaccine X 2021 Aug 2;8:100095. Epub 2021 Apr 2.

International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, United States.

Background: There were about 138 million new episodes of pneumonia and 0.9 million deaths globally in 2015. In Uganda, pneumonia was the fourth leading cause of death in children under five years of age in 2017-18. Read More

View Article and Full-Text PDF

Is it the Right Time to Introduce the Hepatitis B Booster Vaccine in National Immunization Schedule? An Analysis from the Available Evidence.

Indian J Community Med 2021 Jan-Mar;46(1):4-6. Epub 2021 Mar 1.

Department of Community Medicine and School of Public Health, PGIMER, Chandigarh, India.

Hepatitis B virus (HBV) infection is a global health concern, and it is considered one of the deadliest infections in the world, having nearly 1.2 million deaths annually. Around 75% of all global HBV carriers live in the Asia-Pacific region. Read More

View Article and Full-Text PDF

Long -term persistence of antibodies against varicella in fully immunized healthcare workers: an Italian retrospective cohort study.

BMC Infect Dis 2021 May 25;21(1):475. Epub 2021 May 25.

Department of Biomedical Science and Human Oncology, Aldo Moro University of Bari, Piazza Giulio Cesare 11, 70124, Bari, Italy.

Background: Chickenpox is a highly contagious disease caused by the varicella zoster virus (VZV), and in infants, adolescents, adults, pregnant women, and the immunocompromised it can be serious. The best way to prevent chickenpox is immunization with the varicella vaccine. Protective levels of antibodies induced by the varicella vaccine decline over time, but there is currently no formal recommendation for testing anti-varicella zoster virus (VZV) IgG levels in immunized healthcare workers (HCWs). Read More

View Article and Full-Text PDF

Comparison of the immune response following subcutaneous versus intranasal modified-live virus booster vaccination against bovine respiratory disease in pre-weaning beef calves that had received primary vaccination by the intranasal route.

Vet Immunol Immunopathol 2021 Jul 24;237:110254. Epub 2021 May 24.

Group for Reproduction in Animals, Vaccinology and Infectious Diseases (GRAVID™), College of Veterinary Medicine, University of Georgia, Athens, GA 30602-2771, United States.

This study was performed to elucidate whether the route of booster vaccination affects the immune response against respiratory vaccine viruses in pre-weaning beef calves that receive primary intranasal (IN) vaccination during the first month of life. The objective was to compare the serum neutralizing antibody (SNA) titers to BHV1, BRSV, and BPI3V, cytokine mRNA expression and mucosal BHV1- and BRSV-specific IgA in nasal secretions following administration of IN or subcutaneous (SC) modified-live virus (MLV) booster vaccines 60 days after primary IN vaccination in young beef calves. Twenty-one beef calves were administered 2 mL of an IN MLV vaccine containing BHV1, BRSV, and BPI3V (Inforce3®) between one and five weeks of age. Read More

View Article and Full-Text PDF